Background-Lung inflammation precedes the development of hypoxia-induced pulmonary hypertension (HPH); however, its role in the pathogenesis of HPH is poorly understood. We sought to characterize the hypoxic inflammatory response and to elucidate its role in the development of HPH. We also aimed to investigate the mechanisms by which heme oxygenase-1, an anti-inflammatory enzyme, is protective in HPH. Methods and Results-We generated bitransgenic mice that overexpress human heme oxygenase-1 under doxycycline control in an inducible, lung-specific manner. Hypoxic exposure of mice in the absence of doxycycline resulted in early transient accumulation of monocytes/macrophages in the bronchoalveolar lavage. Alveolar macrophages acquired an alternatively activated phenotype (M2) in response to hypoxia, characterized by the expression of found in inflammatory zone-1, arginase-1, and chitinase-3-like-3. A brief 2-day pulse of doxycycline delayed, but did not prevent, the peak of hypoxic inflammation, and could not protect against HPH. In contrast, a 7-day doxycycline treatment sustained high heme oxygenase-1 levels during the entire period of hypoxic inflammation, inhibited macrophage accumulation and activation, induced macrophage interleukin-10 expression, and prevented the development of HPH. Supernatants from hypoxic M2 macrophages promoted the proliferation of pulmonary artery smooth muscle cells, whereas treatment with carbon monoxide, a heme oxygenase-1 enzymatic product, abrogated this effect. Conclusions-Early recruitment and alternative activation of macrophages in hypoxic lungs are critical for the later development of HPH. Heme oxygenase-1 may confer protection from HPH by effectively modifying the macrophage activation state in hypoxia.
P ulmonary arterial hypertension (PAH) is a devastating disease characterized by vasoconstriction and vascular wall remodeling with resultant right ventricular hypertrophy and eventual failure. Despite significant progress in this field, the mechanisms underlying the development of PAH are still obscure. Recently, in an increasing number of studies, lung inflammation has been implicated as a potential maladaptation underlying the development of PAH. Infiltrates of leukocytes and inflammatory mediators have been detected in patients with PAH, [1] [2] [3] and have been reported to contribute to pulmonary vascular remodeling in animal models of disease. 4 -6 Tissue hypoxia, a well-known stimulus for pulmonary hypertension, has also been demonstrated by our group and others to induce an inflammatory response that precedes the development of hypoxia-induced pulmonary hypertension (HPH). [7] [8] [9] Clinical Perspective on p 1995
Among the inflammatory cells implicated in PAH, those of the monocyte/macrophage lineage have been correlated with disease more often. 1,2,8 -10 However, macrophages efficiently respond to environmental signals with remarkable plasticity and undergo different forms of polarized activation that can be roughly categorized as classically activated (M1), alternatively activated (M2), and anti-inflammatory (regulatory) macrophages. 11, 12 Classically activated macrophages are effector phagocytes activated by interferon-␥ and tumor necrosis factor (TNF-␣). They produce inducible nitric oxide synthase and interleukin (IL)-12 and exhibit enhanced microbicidal or tumoricidal capacity. 11 On the other hand, M2-polarized macrophages are activated mostly by IL-4 or IL-13, and, as recently discovered, by CCL2 and IL-6, 13 and they express arginase-1 (Arg-1), found in inflammatory zone-1 (Fizz1), chitinase-3-like-3 (Ym1), and mannose receptor, C type lectin-1. 11, 12, 14 M2 macrophages have been implicated in the pathogenesis of lung and other disorders via their ability to promote trophic, profibrotic, and angiogenic functions. 15, 16 The major characteristic of the third population, regulatory macrophages, is the production of high IL-10 and low IL-12 levels and the promotion of immunosuppression. 11, 14 In the case of PAH, the activation state of the recruited macrophages and their contribution to disease has remained unclear until now.
Heme oxygenase-1 (HO-1) is a major antioxidant and cytoprotective enzyme that catalyzes the degradation of heme to 3 enzymatic end products: carbon monoxide (CO), free Fe 2ϩ , and biliverdin. 17 Heme oxygenase-1 and its enzymatic product, CO, have been reported by our group and others to be protective in HPH. 7,18 -20 This protection, up to now, has been attributed mainly to the relaxation of vascular tone and inhibition of vascular smooth muscle cell proliferation by CO. 21 However, it has been demonstrated that HO-1 7, 17, 22, 23 and CO 24, 25 have potent antiinflammatory properties, some of which may be exerted via the upregulation of the anti-inflammatory cytokine IL-10. 25, 26 Moreover, HO-1-deficient mice develop a chronic oxidative inflammatory state that progresses with age 27 and have a maladaptive response to hypoxia with right ventricular dilation, fibrosis, and inflammation. 18, 28 Therefore, we hypothesized that immunomodulation is a key mechanism of HO-1 protection in PAH.
To characterize in detail the lung inflammatory response caused by hypoxia, to assess its role in pulmonary hypertension, and to investigate the protective properties of HO-1 in this context, we generated a bitransgenic mouse model with doxycycline-inducible, lung-specific expression of HO-1. We report here that hypoxic exposure in the absence of doxycycline provoked a significant monocyte/macrophage accumulation in the bronchoalveolar lavage fluid (BALF) that manifested a phenotype consistent with alternative activation, with upregulated expression of Fizz1, Arg1, Ym1, and mannose receptor, C type lectin-1. Heme oxygenase-1 overexpression by doxycycline treatment inhibited hypoxic macrophage recruitment and activation and resulted in upregulation of IL-10 in macrophages. Supernatants from hypoxic cultures of M2 macrophages promoted proliferation of pulmonary artery smooth muscle cells, whereas CO treatment abrogated this effect. By modulating the timing and duration of HO-1 expression with doxycycline, we were able to either delay or suppress lung inflammation and macrophage activation and, in the latter case, abolish HPH.
Methods
Bitransgenic mice were generated by crossing Balb/c transgenic mice that harbor the tetracycline transcriptional activator (tetON system) under the control of the Clara cell secretory protein promoter with FVB transgenic mice that carry the human HO-1 (hHO-1) transgene under the control of the tetracycline response element ( Figure 1A) . Expression of hHO-1 in the lung was achieved by the addition of 1 mg/mL doxycycline to the drinking water. The CCTA mouse line that lacks the hHO-1 transgene was treated with doxycycline and served as control to eliminate any potential effects imparted by doxycycline itself independently of hHO-1. All animal procedures were approved by the Children's Hospital Boston Animal Care and Use Committee. An expanded Methods section is available in the online-only Data Supplement.
Statistical Analysis
All values are expressed as meanϮSD. Comparison of results between different groups was performed by 1-way ANOVA or Mann-Whitney U test when appropriate with GraphPad InStat (GraphPad Software, San Diego, CA). Values of PϽ0.05 were considered significant.
Results

Lung-Specific, Inducible Expression of Human Heme Oxygenase-1
Based on the design of the bitransgenic model (designated CC77; Figure 1A ), the hHO-1 transgene is under the control of both doxycycline and the Clara cell secretory protein promoter and therefore is inducibly expressed in the lung epithelium. Semiquantitative polymerase chain reaction analysis on total lung RNA with hHO1-specific primers indicates that hHO-1 levels were upregulated with doxycycline treat- HO-1) . A, Bitransgenic mice were generated by crossing lines CCTA and TH77. CCTA harbors the reverse tetracycline transactivator (rtTA) under the control of the 2.3-kb rat Clara cells secretory protein (CCSP) promoter. TH77 harbors a human HO-1 (hHO-1) transgene under the control of 7 copies of the tet operator linked to a minimal cytomegalovirus (CMV) promoter. B, Bitransgenic mice (CC77) were treated with 0.2 or 1 mg/mL dox in the drinking water for 2 to 12 days, and semiquantitative polymerase chain reaction analysis on total lung RNA for hHO1 and the housekeeping gene, GADPH, is depicted. The SHO1 (transgenics constitutively expressing hHO-1 in lung epithelium) and FVB (wildtype) mouse strains served as positive and negative controls, respectively. The primers used target a divergent region on HO-1 mRNA and do not amplify endogenous murine HO-1 transcripts. C, Western Blot analysis of HO-1 protein in total lung extracts of CC77 and CCTA mice. Note that the antibody used detects both the dox-regulated human HO-1 and the endogenous murine HO-1. Heme oxygenase-2 (HO-2) was used as an internal control. ment in a dose-dependent manner but remained undetectable in the absence of doxycycline ( Figure 1B ). Using an antibody that detects both human and murine HO-1, we detected profoundly elevated protein levels of HO-1 in the lungs of doxycycline-treated CC77 mice but not in CCTA mice ( Figure 1C ).
Sustained Induction of Heme Oxygenase-1 Prevents Hypoxia-Induced Pulmonary Hypertension
The development of PAH in our model was assessed by the measurement of right ventricular systolic pressure, the Fulton Index, and the medial wall thickness index. The Fulton Index, the ratio of right ventricle weight to left ventricle plus septum weight, represents a hallmark of right ventricular hypertrophy resulting from increased right ventricle pressure afterload. The medial wall thickness index was estimated from the histological sections of pulmonary arterioles stained with ␣-smooth muscle actin. Right ventricular systolic pressure, the Fulton Index, and the medial wall thickness index were significantly elevated as early as 7 days of hypoxia in both bitransgenics (CC77) and controls (CCTA) (Figure 2A through 2C) . Doxycycline administration for the entire course of hypoxia prevented the increase in right ventricular systolic pressure, the Fulton Index, and the medial wall thickness index in the bitransgenic mice but not in the controls (Figure 2 ).
Immunostaining of pulmonary arterioles for ␣-smooth muscle actin revealed thickened and remodeled medial vascular walls in lung sections of hypoxic mice. This pathology was absent in hypoxic mice treated with doxycycline ( Figure 2D ).
Hypoxia Induces Monocyte/Macrophage Infiltration and Lung Cytokine Production That Is Ameliorated by Heme Oxygenase-1 and its Enzymatic Product, Carbon Monoxide
To track the inflammatory response at the initial stages of hypoxic exposure and before the development of hypertension, animals were exposed to hypoxia, and a temporal profile of the cell content in BALF was performed. More than 95% of the isolated BALF cells were CD45-positive leukocytes ( Figure Figure 3A ). Under these conditions, only a subtle increase in BALF neutrophils and T lymphocytes was observed (data not shown). When hypoxic exposure was begun, the numbers of monocytes/macrophages were significantly increased in the BALF of control hypoxic mice, reaching a peak at 2 days of hypoxia and dropping significantly by 7 days but remaining slightly elevated compared with normoxic animals ( Figure 3B ). Doxycycline administration had a suppressive effect on the accumulation of cells at all time intervals investigated ( Figure 3B ). Doxycycline treatment of the control mice (CCTA) had no impact on monocyte/macrophage accumulation, establishing that inhibition of cell infiltrate is due specifically to HO-1 overexpression and is not an artifact of doxycycline treatment ( Figure 3C ).
To identify the specific enzymatic product of HO-1, CO, and/or biliverdin that is responsible for suppressing the peak of inflammation at 2 days of hypoxia, we exposed animals to intermittent inhalation of CO (250 ppm for 1 hour twice a day) and/or biliverdin injections (50 mol/kg IP twice a day). Intraperitoneal PBS injections served as control. Inhaled CO or CO plus biliverdin, but not biliverdin alone, was effective in inhibiting the inflammatory cell infiltrate in the BALF at levels comparable to doxycycline treatment ( Figure 3C ).
In addition to the accumulation of macrophages, several cytokines/chemokines were upregulated in the BALF of hypoxic mice ( Figure II in the online-only Data Supplement). In as early as 2 and 4 days of hypoxia, upregulation of fibroblast growth factor ␤, IL-1␤, macrophage inflammatory Interestingly, a striking alteration of macrophage morphology in cytospin preparations of BALF-isolated macrophages was observed at 4 days of hypoxia, characterized by cytoplasmic enlargement in a population of cells. This phenotype is consistent with activation and was not detected in any of the macrophages isolated from doxycycline-treated mice ( Figure 3D ).
Hypoxia Induces Alternative Activation of Macrophages: Suppressive Effect of Heme Oxygenase-1
The observation that macrophage morphology was altered in response to hypoxia led us to further investigate the potential activation state of hypoxic macrophages. Quantitative polymerase chain reaction analysis of BALF-isolated alveolar macrophages from CC77 bitransgenic mice revealed an induction of well-defined markers of M2 macrophages in hypoxic mice, including Arg1, Fizz1, Ym1 ( Figure 4A) , and mannose receptor, C type lectin-1 (data not shown). The peak expression occurred at 4 days of hypoxia and remained upregulated for at least 14 days. In addition, Fizz1 was secreted in the BALF of hypoxic mice ( Figure 4B ). In contrast, there was no change in the mRNA levels of markers of M1 macrophage phenotype such as inducible nitric oxide synthase, TNF-␣, and IL-12␤ (IL-12p40) or the costimulatory molecules, CD80/86, essential in the process of antigen presentation ( Figure III in the online-only Data Supplement). Urea production, indicative of arginase activity, was also upregulated in in vivo hypoxic alveolar macrophages ( Figure  4C ); this increase in enzymatic activity was due to Arg1 because Arg1 mRNA levels were induced 9.1Ϯ3.4-fold after 4 days of hypoxic exposure, whereas Arg2 mRNA levels were 0.6Ϯ0.1 of their normoxic value at this time point. Inducible nitric oxide synthase activity, as assessed by nitrite and nitrate production in the BALF, remained unchanged ( Figure 4D ). Doxycycline administration effectively suppressed all markers of alternative activation ( Figure 4A through 4C), whereas these markers were not suppressed in the CCTA line treated with doxycycline ( Figure 4B and 4C and Figure IVA in the online-only Data Supplement). Immunostaining revealed that 10.8Ϯ2.7% (35.5Ϯ8.9ϫ10 3 , meanϮSD) of the macrophages were Fizz1 positive, whereas in the presence of doxycycline, this number was reduced to 2.17Ϯ0.6% (5.1Ϯ1.4ϫ10 3 , meanϮ SD; PϽ0.01; Figure 5A ). Immunofluorescent staining confirmed the localization of Fizz1 and the absence of inducible nitric oxide synthase in the cytoplasm of hypoxic macrophages ( Figure 5B and 5C ). Apart from the slight elevation of the Th2 cytokines IL-13 and IL-4 in the BALF of hypoxic mice, we investigated the potential presence of other noncanonical inducers of M2 polarization. Thus, we assessed the mRNA levels of CCL2 and IL-6 in total lung extracts by quantitative polymerase chain reaction. CCL2 and IL-6 mRNA was robustly upregulated soon after hypoxic exposure but was significantly suppressed in the presence of doxycycline ( Figure 
Heme Oxygenase-1 Promotes the Expression of Interleukin-10 in Alveolar Macrophages
In an effort to further evaluate the effect of HO-1 on macrophage phenotype, mRNA and protein levels of IL-10, a well-documented anti-inflammatory mediator, were directly assessed in freshly isolated alveolar macrophages. Interleukin-10 was significantly elevated in alveolar macrophages derived from hypoxic mice treated with doxycycline ( Figure 6 ). Doxycycline treatment in the CCTA line failed to upregulate IL-10 ( Figure IVB in the online-only Data Supplement), establishing that the observed effect is HO-1 dependent. Furthermore, the number of regulatory macrophages expressing IL-10 (CD11cϩ, IL-10ϩ) under hypoxia was assessed by flow cytometry to be increased 4-to 9-fold with doxycycline treatment, comprising slightly Ͻ10% of the total macrophage population in BALF (data not shown).
Early Monocyte/Macrophage Accumulation Is Critical for the Later Development of Pulmonary Hypertension
To determine whether this early inflammatory response is essential for the later development of HPH and whether inducible expression of HO-1 at defined intervals during this process modulates the disease, we exposed the bitransgenic mice to doxycycline for various time periods. In addition to HO-1) . A, Quantitative polymerase chain reaction analysis of hypoxic alveolar macrophage mRNA isolated from bitransgenic mice (CC77) revealed increased found in inflammatory zone-1 (Fizz1), arginase-1 (Arg1), and chitinase-3-like-3 (Ym1) levels that were suppressed with doxycycline (dox). B, Western blot analysis for Fizz1 on bronchoalveolar lavage fluid (BALF) from normoxic mice (Nrm) and mice exposed to hypoxia for 4 days-dox (Hypdox) or with dox treatment (Hypϩdox); IgA served as internal control. C, Arginase activity (U/L) was assessed by urea formation in alveolar macrophages from normoxic and hypoxic animals. D, Inducible nitric oxide synthase activity was estimated by the levels of nitrite and nitrate in the BALF of hypoxic mice. Supernatants from RAW 264.7 macrophages stimulated with 100 g/mL lipopolysaccharide (LPS) Escherichia coli and 100 U/mL interferon-␥ (INF-␥) for 48 hours served as positive controls. MeanϮSD is depicted for nՆ6 mice per group. *PϽ0.05, **PϽ0.01, ***PϽ0.001 relative to normoxia; #PϽ0.05, ##PϽ0.01, ###PϽ0.001 relative to hypoxia-dox. control animals exposed to hypoxia for 3 weeks in the absence of doxycycline, 1 group of littermates received doxycycline continuously for 3 weeks, and in 2 other groups, doxycycline was removed from the drinking water at 2 or 7 days of hypoxia. In all groups, animals remained in hypoxia for the entire 3-week period. On removal of doxycycline, hHO-1 mRNA levels returned to baseline within 3 days ( Figure 7A and 7B) .
A short 2-day pulse of doxycycline at the onset of hypoxia caused a delay in the peak of macrophage recruitment in the BALF from 2 to 7 days, a time when HO-1 levels were reduced to baseline ( Figure 7A ). In the same group of animals, development of pulmonary hypertension, as assessed by right ventricular systolic pressure, the Fulton Index, the medial wall thickness index, and histology of vascular remodeling, was not prevented (Figure 7C  through 7F ). In the case of a more prolonged, yet still transient, administration of doxycycline for 7 days, there was no macrophage influx even when HO-1 had reached baseline low levels, and pulmonary hypertension was completely prevented at 3 weeks (Figure 7B through 7F) .
Alternative Macrophage Activation Is Associated With the Development of Hypoxia-Induced Pulmonary Hypertension In Vivo and Enhances Pulmonary Artery Smooth Muscle Cell Proliferation In Vitro
In agreement with macrophage numbers, M2 markers followed a similar pattern ( Figure 8A ). In the group in which doxycycline was removed after 2 days of hypoxic exposure and HPH was not prevented, mRNA levels of Fizz1, Arg1, and Ym1 increased 4 days after HO-1 levels had fallen to baseline ( Figure 8A ). However, in the group that received doxycycline for the first 7 days of hypoxia and the later development of hypertension was prevented, levels of Fizz1, Arg1, and Ym1 remained suppressed for all time periods examined ( Figure 8B ). Interestingly, in only the 7-day doxycycline treatment group, the anti-inflammatory marker IL-10 remained sustainably elevated above baseline ( Figure 8A and 8B) . Early monocyte/macrophage accumulation is critical for the later development of hypoxia-induced pulmonary hypertension. Heme oxygenase-1 (HO-1) was transiently overexpressed in hypoxic mouse lung. A, Doxycycline (dox) administered at days Ϫ2 to 2 of hypoxic exposure (2 days) delays but does not prevent the peak of macrophage accumulation when HO-1 levels return to baseline. hHO-1 indicates human HO-1. B, Doxycycline administered at days Ϫ2 to 7 of hypoxic exposure (7 days) prevents the peak of macrophage accumulation for Ͼ12 days after HO-1 levels have returned to baseline. M indicates macrophage numbers. Right ventricular systolic pressure (RVSP; C), the Fulton Index (D), and medial wall thickness index (E) were elevated in mice that received the 2-day pulse but not in mice that received the 77-day pulse of dox. F, Representative immunostaining for ␣-smooth muscle actin of lung sections from mice exposed to hypoxia for 21 days that had previously received dox for either 2 or 7 days compared with normoxia. Numbers represent meanϮSD; nՆ6 animals per group. *PϽ0.05, **PϽ0.01, ***PϽ0.001 relative to normoxia; ##PϽ0.01, ###PϽ0.001 relative to hypoxia-dox.
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Interleukin-10 mRNA levels were also upregulated in primary alveolar macrophages cultured in vitro under hypoxic conditions (0.5% O 2 ) and treated with CO (500 ppm; Figure 8C ). This suggests that CO release on HO-1 induction in this system is the trigger for IL-10 induction in macrophages.
Supernatants of primary alveolar macrophages that were cultured in vitro under hypoxic conditions (0.5% oxygen) or normoxic macrophages treated with IL-4 (20 ng/mL) had high levels of Fizz1 and low levels of IL-10, and were able to stimulate pulmonary artery smooth muscle cell proliferation ( Figure 8D ). However, supernatants from CO-treated hypoxic macrophages had reduced levels of Fizz1 and elevated IL-10 and had no proliferative effect on pulmonary artery smooth muscle cells ( Figure 8D ). Exogenous administration of IL-10 on pulmonary artery smooth muscle cells treated with hypoxic macrophage supernatants had no direct suppressive effect on their proliferation ( Figure VII in the online-only Data Supplement). Arg1, Fizz1, and Ym1 mRNA was upregulated in both IL-4 -and hypoxia-stimulated macrophages, whereas neither platelet derived growth factor-BB nor the M1 specific markers IL-12 and TNF-␣ were affected ( Figure 8C , Figure VI in the online-only Data Supplement, and data not shown). CO treatment suppressed the upregulation of the above M2 markers in both the IL-4 -and hypoxia-stimulated macrophages ( Figure 8C , Figure VI in the online-only Data Supplement, and data not shown).
Discussion
In our bitransgenic mouse model, we demonstrate that hypoxia provokes an accumulation of alternatively activated alveolar macrophages that precedes the development of pulmonary hypertension and appears to play a critical role in the pathogenesis of disease. Overexpression of HO-1 induced a switch in macrophage polarity toward an anti-inflammatory phenotype, and this effect was associated with protection from HPH.
Hypoxia resulted in alveolar inflammation that consisted predominantly of macrophages. These findings correlate with the fact that macrophages tend to accumulate in poorly vascularized areas with low oxygen tension, 29 and correlates with previous studies in HPH that highlighted the predominant role of the monocyte/macrophage lineage in modulating vascular remodeling. 8 Additionally, we found that hypoxia in vivo and in vitro polarized the population of alveolar macrophages toward the M2 phenotype. Hypoxic microenvironment is also a hallmark feature of tumors, and similar to the hypoxic macrophages in our model, the tumor-associated macrophages exhibit an M2-like phenotype. 11, 29 The cellautonomous M2 polarization in in vitro hypoxic conditions, the upregulation in vivo of mRNA levels of 2 recently recognized noncanonical inducers of M2 polarization, CCL2 and IL-6, 13 and the increased IL-13 and IL-4 cytokine levels in the BALF of hypoxic mice support the M2-like activation in our hypoxic model. Furthermore, Fizz1, an M2-specific marker, is a hypoxia-inducible molecule, also designated hypoxia-induced mitogenic factor. 30 However, contrary to our findings, 2 previous studies reported upregulation of TNF-␣, 31 IL-12, and interferon-␥ 32 in hypoxic macrophages. We believe that our in vivo studies most closely approximate the disease physiology because the first of the 2 previous studies was performed only in vitro using isolated rat alveolar macrophages in a sepsis-induced hypoxia model and the second study was conducted on peritoneal macrophages.
Our finding that the presence of M2 macrophages is associated with the development of HPH in vivo and pulmonary artery smooth muscle cell proliferation in vitro suggests that these polarized trophic macrophages may play a significant role in the later development of pulmonary hypertension. Indeed, enhanced polyamine and L-proline synthesis caused by Arg1 has been shown to contribute to vascular damage and remodeling, and elevated Arg1 in lungs of hypoxic mice has been associated with increased severity of PAH. 33, 34 Fizz1 has been recently reported to have mitogenic, angiogenic, and vasoconstrictive properties that are associated with pulmonary vascular remodeling. 5, 30, 35 Its human homolog, resistin-like molecule ␤, has also been detected in patients with scleroderma-associated pulmonary hypertension. 36 However, to the best of our knowledge, this is the first study to propose a link between alternatively activated macrophages and the development of HPH. One potential mechanism of action of alternatively activated macrophages may be the secretion of Fizz1, the overexpression of which has been reported to lead to PAH. 5 Further studies are required to determine the specific mediators from the secretome of M2 macrophages that may be contributing factors in the signaling cascade leading to HPH. In agreement with our findings, previous studies have shown that Th2 cytokines, as well as IL-6 and CCL2, induce M2 and have been implicated in human pulmonary disease and animal models of PAH. 3, 6, 37 Overexpression of HO-1 in our bitransgenic model provoked a robust anti-inflammatory effect. It suppressed macrophage accumulation, M2 activation, and cytokine production in the lungs and prevented the subsequent development of pulmonary hypertension. Carbon monoxide appeared to be the key HO-1 effector inhibiting macrophage accumulation in the BALF and suppressing the expression of M2 markers in vitro. This observation is in agreement with previous studies in which HO-1 and CO were reported to have potent anti-inflammatory effects. 7, 25 Endogenous HO-1 is upregulated in hypoxia as a compensatory mechanism, 19 but its brief upregulation is not adequate to prevent hypoxia-induced inflammation and HPH, and only a more sustained enhancement of HO-1 expression can be protective in HPH. 7 For this reason, it is not surprising that a 2-day upregulation of HO-1 with doxycycline only postponed inflammation and did not protect from the development of HPH. Interestingly, HO-1 induction for 7 days, covering the entire period of hypoxia-induced inflammation, was sufficient to prevent the later development of HPH. Indeed, 7-day upregulation of HO-1 suppressed the inflammatory response even 2 weeks after the return of HO-1 to baseline levels, despite continuous hypoxia.
Because the switch in macrophage phenotype occurred within the first 4 days of hypoxia, we hypothesize that the enhancement of HO-1 during this critical period may act as a pivot to shift the balance of immune response from proinflammatory toward immunosuppressive. In support of this, lung HO-1 overexpression upregulated IL-10 in hypoxic macrophages and increased the number of IL-10 -expressing regulatory macrophages in the BALF. Because CO could upregulate IL-10 in the in vitro cultured hypoxic macrophages, it seems to be a major effector molecule of HO-1 immunomodulation. In agreement with our findings, HO-1 and exogenous CO have previously been reported to increase IL-10 expression in macrophages in vivo and in vitro. 25,38 -40 Interestingly, IL-10 remained elevated even 2 weeks after HO-1 expression returned to baseline levels. These findings point to a switch in immunoregulation triggered by HO-1 during an early critical period, and whose presence was no longer essential, at least for the subsequent 2 weeks of hypoxia. Elevated IL-10 levels were also associated with protection from HPH, and IL-10 expression has been reported to protect from monocrotaline-induced PAH in rats. 4 We show that macrophages were the source of IL-10, but it remains unclear whether they are also a target of this cytokine. Because IL-10 is a pleiotrophic cytokine, it may act in an autocrine and paracrine manner to affect many different cell types besides macrophages. However, IL-10 did not have direct antiproliferative effects on pulmonary artery smooth muscle cells in our in vitro model, indicating that HO-1 and CO may also have anti-inflammatory functions independently of IL-10. Further studies are required to decipher the role of IL-10 pathway in the protection from HPH development and the mechanism of sustained protection from HPH conferred by a transient immunomodulatory event.
Conclusions
The present study demonstrates a link between macrophage accumulation and M2 activation and the promotion of HPH. On the basis of our findings, targeting the elimination or inactivation of this subset of macrophages may ameliorate the outcome of disease and improve the long-term prognosis of PAH. Importantly, M2 activation may serve as a biomarker to identify a therapeutic window for anti-inflammatory treatments and obviate the need for long-term therapies. lis). Dr Vergadi was supported in part by the Propontis Foundation (Athens, Greece) and the State Scholarships Foundation of Greece as a graduate student in the Graduate Program in Molecular Basis of Human Disease (University of Crete School of Medicine).
